Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma: Long-term treatment results of a randomized study

Strahlentherapie und Onkologie

Volumn 179, Issue 6, 2003, Pages 377-384

  Tačev, Tačo ^a   Ptáčková, Blanka ^a   Strnad, Vratislav ^b  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Brachytherapy; Californium 252(252Cf); Carcinoma of the cervix uteri (cervical carcinoma); Treatment results

Indexed keywords

CALIFORNIUM 252; CESIUM 137; RADON; RADON 226; UNCLASSIFIED DRUG; CALIFORNIUM;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GAMMA RADIATION; HUMAN; MAJOR CLINICAL STUDY; RADIATION DOSE; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; ADULT; AGED; COMPARATIVE STUDY; FOLLOW UP; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TIME; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AGED; BRACHYTHERAPY; CALIFORNIUM; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GAMMA RAYS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 0642315364     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-003-1005-4     Document Type: Article

References (37)

1. Bedford JS, Hall EG. Survival of He-La cells cultured in vitro and exposed to protracted gamma radiation. Int J Radiat Biol 1963;7:377-80.
2. 252 brachytherapy at Oxford. In: Mewissen DJ, ed. Californium-252: radiobiology and medical applications. Proceedings of the Brussels Symposium on Californium-252 Utilisation, Brussels, Belgium, April 1976. Aiken: SC, USA 1979:65-75.
3. Castro, JR, Oliver GD, Withers HR, Almond PR. Experience with californium-252 in clinical radiotherapy. AJR Am J Roentgenol 1973;117:182-94.
4. Feola JM, Nava A, Maruyama Y. Biological effects of Cf-252 neutrons at low dose rate. Int J Radiat Biol 1982;41:33-46.
5. Fields PR. Transplutonium elements in thermonuclear test debris. Phys Rev 1956;102:180.
6. Gragg RL, Huphrey PM, Thames HD Jr, Meyn RE. The response of Chinese hamster ovary cells to fast neutron radiotherapy beams: III. Variation in relative biological effectiveness with position in the cell cycle. Radiat Res 1978;76:283-9.
7. Hall EJ, A comparison of radium and californium-252 using cultured mammalian cells. Radiology 1972;102:173-9.
8. Hall EJ, Rofzin-Towle LA, Colvett RD. RBE and OER determination for radium and californium-252. Radiology 1974;110:699-701.
9. Hall EJ, Rossi HH, Roizin L. Low dose irradiation of mammalian cells with radium and californium-252. Radiology 1971;102:445-51.
10. Hänsgen G, Kuhnt T, Pigorsch S, Straus H, Dunst J. Adjuvante simultane Radiochemotherapie nach operiertem Uteruszervixkarzinom in der High-Risk-Situation. Ergebnisse einer Pilotuntersuchung. Strahlenther Onkol 2002;178:71-7.
11. Lockhard RZ, Elkind MM, Moses WB. Radiation response of mammalian cells grown in culture: II. Survival and recovery characteristics of several sub-cultures of He-La S cells after X-irradiation. J Natl Cancer Inst 1961;27: 1392-404.
12. Maruyama Y, Beach JL, Feola J. Scheduling of hypoxic tumor therapy using neutron brachytherapy. Radiology 1980;137:775-8.
13. Maruyama Y, Feola J, Beach JL. A tumor/normal tissue advantage for low dose rate neutron brachytherapy. Int J Radiat Oncol Biol Phys 1983;9: 1715-21.
14. Maruyama Y, Kryscio R, Van Nagel JR, Yoneda J, Donaldson E, Hanson M, Beach JL. Clinical that of Cf-252 neutron brachytherapy for advanced cervical cancer. Int J Radiat Oncol Biol Phys 1983;11:1475-82.
15. Maruyama Y, Yoneda J, Krolikiewicz H, Mendiondo O, Beach JI, Coffey CW, Thomson D, Wilson LC, Feola J, Van Nagell JR, Donaldson ES, Powell D. A clinical that for advanced cervico-vaginal pelvis carcinomas using californium-252 fast neutron therapy: report of early responses. Int J Radiat Oncol Biol Phys 1980;6:1629-37.
16. Puck TT, Marcus PI. Action of X-rays on mammalian cells. J Exp Med 1959; 103:653-66.
17. Schlea CS, Stoddard DH. Californium isotopes proposed for intracavitary and interstitial radiation therapy with neutrons. Nature 1965;206: 1058-9.
18. Seydel G, The clinical use of californium-252 sources in the United States. In: Mewissen DJ, ed. Californium-252: radiobiology and medical applications. Proceedings of the Brussels Symposium on Californium-252 Utilisation, Brussels, Belgium, April 1976. Aiken: SC, USA 1979:77-82.
19. Steel GG, Peacock JH. Why are some human tumours more radiosensitive than others? Radiother Oncol 1989;15:63-72.
20. Strauss HG, Kuhnt T, Laban C, Puschmann D, Pigorsch S, Dunst J, Koelbl H, Haensgen G. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol 2002;178:378-85.
21. Tačev T, Kryštof V, Ott O, Rašovská O, Strnad V. Technical equipment for workroom with californium-252 used for the gamma neutron brachytherapy. Strahlenther Onkol 1988;164:296-9.
22. Tačev T, Kryštof V, Rašovska O, Strnad V. Studium intrakavitarni aplikace kalifornia-252 pri Ca cervicis uteri a vyuziti plynne hypoxie pd zevnim ozareni. Zaverecna zprava vyzkumnehoukolu P12-561-817-06/07 SPTR v roce 1990. [A study of intracavitary application of californium-252 in cancer of the uterine cervix and the use of hypoxytherapy in external radiation. Final Report of Research Project No P12-561-817-06/07 SPTR in 1990.]
23. Tačev T, Prokeš B, Strnad V, Rašovská O, Kryštof V, Nikodemová D. Effect of small doses of Cf-252 on the tumour regression in cervix uteri during combined radiotherapy. Strahlenther Onkol 1989;165:837-43.
24. Tačev T, Ptáčková B, Vacek A, Rašovská O, Prokeš B, Strnad V, Kryštof V. The relationship of Cf-252 and Ra-226 radiation doses and the reoxygenation to regression of the cervix uteri tumor. Part II. Preliminary results in advanced cervical carcinoma. In: Wierzbicki JG, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI series 3, high technology, vol 29. Dordrecht-Boston-London: Kluwer Academic, 1997:77-82.
25. Tačev T, Strnad V, Vacek A. Radiotherapy of cervix uteri carcinoma with 252-Cf and hypoxyradiotherapy in the course of external irradiation. Radiosensitization Newsletter 1991;10:10-2.
26. Tačev T, Strnad V, Vacek A, Rašovská O, Prokeš B, Ptáčková B, Kryštof V. Radiotherapy of cervix uteri carcinoma with Cf-252 implant and external hypoxyradiotherapy. Nucl Sci Applic 1991;4:201-12.
27. Tačev T, Vacek A, Prokeš B, Rašovská O, Ptášková B, Strnad V, Kryštof V. The relationship of Cf-252 and Ra-226 radiation doses to the reoxygenation and regression of cervix uteri tumors. Part I. Clinical experimental study. In: Wierzbicki JG, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI series 3, high technology, vol 29. Dordrecht-Boston-London: Kluwer Academic, 1997:57-75.
28. Thomson SG, Street K, Chiroso A, Seaborg GT. The new element californium (atomic number 98). Phys Rev 1950;80:790-6.
29. Todd P. Biological aspects of high LET radiation therapy. Radiology 1977; 125:493-9.
30. Vallejo A, Hilaris BS, Anderson LL. Califomium-252 interstitial implantation: a clinical study at Memorial Hospital. Int J Radiat Oncol Biol Phys 1977;2:731-7.
31. Van Outten LM, Reoxygenation of hypoxic tumor cells. Strahlentherapie 1977;153:380-3.
32. Vtyurin BM, Ivanov VN, Konopljanikov AG, Cyb AF, Karelin KA, Elisjutin GP, Komar VJ, Abdulajev VD, Nikišin BK. Effekty nejtronnogo i gama uzlucenij istocnikov na osnove Cf-252. [The effect of neutron and gamma irradiation emanating from Cf-252 sources.] Moskva: Energoatomizdat, 1986.
33. Vtyudn BM, Ivanov VN, Medvedev VS, Galantseova GP, Abdulkadyrov SA, Ivanova LF, Petrovskaja GA, Plichko V. Californium-252 interstitial implants in carcinoma of the tongue. Int J Radiat Oncol Biol Phys 1985; 11:441-9.
34. Wiernik G, Young CMA. Late effects of californium-252 therapy. In: Barendsen GW, ed. High LET radiations in clinical radiotherapy. Oxford: Pergamon Press; 1979:206-7.
35. Wierzbicki JG, ed. Californium-252 isotope for 21st century radiotherapy. NATO ASI series 3, high technology, vol 29. Dordrecht-Boston-London: Kluwer Academic, 1997.
36. Yaes RJ. Tumour heterogenity, tumor size and radioresistance. Int J Radiat Oncol Biol Phys 1989;7:993-1005.
37. Yaes RJ, Berner B, Yoneda J, Feola JM, Maruyama Y. Explanation for the efficacy of early versus delayed californium brachytherapy for bulky cervix cancer. Nucl Sci Applic 1991;4:107-11.